EVENTS | VIEW CALENDAR
Galapagos initiates Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients
MECHELEN, Belgium—Galapagos NV announced on April 6 the start of its exploratory Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis (IPF) patients, named FLORA.
FLORA is a randomized, double-blind, placebo-controlled study investigating a once-daily oral dose of GLPG1690 administered for 12 weeks in 24 IPF patients. Primary objectives of the study are to assess safety, tolerability, pharmacokinetics and pharmacodynamics of GLPG1690 in an IPF patient population. Target engagement will be measured by lysophosphatidic acid in plasma and bronchoalveolar lavage fluid, both at baseline and through 12 weeks of treatment. Secondary objectives include the evaluation of lung function, changes in disease biomarkers and quality of life. Galapagos expects to complete patient recruitment before end 2016, and to report topline results in Q2 2017.
GLPG1690 is a small-molecule inhibitor of autotaxin and fully proprietary to Galapagos.
“We identified the autotaxin target using our proprietary target discovery platform and developed molecule GLPG1690 as an inhibitor of this target. GLPG1690 shows promising results in relevant preclinical models for IPF, and there is growing evidence in scientific literature that autotaxin plays a role in this disease. We are pleased to be able to investigate the effect of GLPG1690 in IPF patients and look forward to seeing the results in the first half of next year,” said Dr. Piet Wigerinck, chief scientific officer of Galapagos.
IPF is a chronic, relentlessly progressive fibrotic disorder of the lungs that typically affects adults over the age of 40.